Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Year-end Financial Results on June 15, 2018
June 11, 2018 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA
May 29, 2018 07:30 ET
|
Elite Pharmaceuticals, Inc.; Glenmark Pharmaceuticals, Inc., USA
NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals,...
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
January 30, 2018 08:35 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017
November 09, 2017 16:59 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals to Present ELI-200 (SequestOx™) Data at PAINWeek 2017 National Conference
August 30, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today it will present data for ELI-200 at PAINWeek 2017 National...
Elite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx™
July 07, 2017 12:47 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported topline results from a pivotal bioequivalence fed study for...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call Information
June 14, 2017 16:58 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
May 25, 2017 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™
March 13, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its...
Elite Reports On SequestOx™ FDA End-of-Review Meeting
January 23, 2017 08:18 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported the Company received official minutes from its December 21, 2016...